We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AL101

News List

GSK and Alector announce global collaboration in immuno-neurology worldpharmanews
July 05, 2021
GlaxoSmithKline plc and Alector, announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
Ayala Pharmaceuticals granted US FDA fast track designation for AL101 to treat recurrent or metastatic adenoid cystic carcinoma pharmaceutical-business-review
March 05, 2020
Ayala Pharmaceuticals, a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers ...